Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis

NCT03912259 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03912259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03912259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2018
Completion date
February 14, 2020
Enrollment
165 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis